A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring

• Egile Nagusiak: Christeen Samuel (Egilea), Hannah Cornman (Egilea), Anusha Kambala (Egilea), Shawn G. Kwatra (Egilea)
• Formatua: Liburua
• Argitaratua: Adis, Springer Healthcare, 2023-02-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a spectrum of burdensome dermatologic conditions. The US Food and Drug Administration (FDA) recently placed a black box warning on this class of medications due to safety concerns based on data from studies...